eli lilly retatrutide ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide, the next generation of

Did you hear about orforglipron, the new GLP-1 pill in the headlines this week

The GLP-1 Market size was valued at USD 52.82 billion in 2025 and is expected to grow at a CAGR of 10.9% from 2026 to 2034.

Harvard geneticist David Sinclair reveals a rare but serious blindness risk linked to GLP-1 drugs, estimating 20,00030,000 NAION cases per year in

Take our quick eligibility test to determine if you qualify for GLP-1 weight management treatment.

FDA-approved prescribing information for semaglutide and tirzepatide both indicate use "as an adjunct to a reduced-calorie diet and increased physical activity."What's been missing is the actuarial proof

Plus, the importance of monitoring metabolic health.